

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

January 8, 2013

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

Catalyst Pharmaceutical Partners, Inc.

File No. 001-33057 - CF# 28967

Catalyst Pharmaceutical Partners, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from Exhibit 10.2 to a Form 8-K filed on October 31, 2012, as refiled with fewer redactions as Exhibit 10.1 to a Form 8-K/A filed on January 4, 2013.

Based on representations by Catalyst Pharmaceutical Partners, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.2 through October 26, 2022

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Michael Seaman
Special Counsel